Search
In this Commentary article, as part of the 100-year celebrations of the journal, we reflect on the contribution of articles published in ICB in the field of tumor immunology. A highlight is a series of interviews conducted with three Australian-based ICB authors who have contributed key papers over the years: Rajiv Khanna, Delia Nelson and Ian Frazer.
Immune checkpoint therapy (ICT) causes durable tumour responses in a subgroup of patients, but it is not well known how T cell receptor beta (TCRβ) repertoire dynamics contribute to the therapeutic response.
Rennae's son Samuel was diagnosed with stage 4 neuroblastoma 13 years ago, and was originally given a 20% chance of survival. She bravely shares their story.
A The Kids Research Institute Australia researcher aiming to reduce the high rate of relapse in children after cancer surgery has won a prestigious post-doctoral fellowship from the Forrest Foundation.
Australian Lions Childhood Cancer Research Foundation has announced it will provide $1.05 million of funding to The Kids Research Institute Australia.
The Kids Research Institute Australia and Perth Children’s Hospital will lead an international clinical trial of a novel drug combination they hope will increase cure rates for one of the most aggressive forms of childhood brain cancer.
The Kids cancer researcher & clinician Dr Nick Gottardo has been announced as the recipient of an Innovation Grant from the Cure Brain Cancer Foundation.
Invasive fungal disease (IFD) remains a challenging complication of treatment for paediatric acute leukaemia. Consensus fungal treatment guidelines recommend withholding chemotherapy to facilitate immune recovery in this setting, yet prolonged delays in leukaemia therapy increase risk of relapse.
Invasive fungal disease (IFD) is a common and important complication in children with acute myeloid leukaemia (AML). We describe the epidemiology of IFD in a large multicentre cohort of children with AML.
Eight The Kids Research Institute Australia researchers are among those who have received grant funding from the Telethon-Perth Children’s Hospital Research Fund (TPCHRF).